Sareum Holdings Plc · LSE:SAR
Sareum — Investor Presentation (August 2022)
15 slides from Sareum's investor presentation, August 2022
Slide 1: Specialists in Small Molecule Drug Development
Specialists in Small Molecule Drug Development August 2022 Dr Stephen Parker, Chairman Dr Tim Mitchell, CEO and Co-Founder Dr John Reader, CSO and Co-Founder www.sareum.co.uk
Slide 2: Disclaimer
Disclaimer The information contained in this document (“Presentation”) is directed at (i) members or creditors of a corporate body within the meaning of Article 43 of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005, as amended ("Order"), (ii) persons who have profession
Slide 3: Presenters
Presenters: • Tim Mitchell, Chief Executive Officer and co-founder • John Reader, Chief Scientific Officer and co-founder www.sareum.co.uk 3
Slide 4: Company overview
Company overview • Sareum is a clinical stage small molecule drug development company developing next generation kinase inhibitors for autoimmune disease and cancer • Led by a highly experienced team with expertise in kinase inhibition and decades of experience in R&D and public company management •
Slide 5: Recent Highlights
Recent Highlights • SDC-1801 – Autoimmune diseases with a focus on psoriasis • CTA application for a Phase 1a/b clinical trial with SDC-1801 submitted July 2022 • Plans in place to initiate clinical trials in healthy volunteers and psoriasis patients, commencing in Q4 2022* TYK2/JAK1 • Up to 120 hea
Slide 6: TYK2/JAK1 Kinase inhibition expertise
Kinase inhibition expertise TYK2/JAK1 www.sareum.co.uk 6
Slide 7: JAK Inhibition on Signalling of Key Immunoregulatory Cytokines
JAK Inhibition on Signalling of Key Immunoregulatory Cytokines O’Shea J, et al. Immunity 2012;36(4);542-550 RA, Psoriasis, IBD, Lupus, Therapeutic Resistance to I/O, Resistance to I/O, Psoriasis, IBD, RA, Lupus RA, respiratory failure opportunities Viral/bacterial from viral infections Viral/bacteri
Slide 8: TYK2/JAK1 Inhibitors are Emerging Targets of Increasing Industry Interest
TYK2/JAK1 Inhibitors are Emerging Targets of Increasing Industry Interest • The JAK cell signalling family (TYK2, JAK1, JAK2, JAK3) is an area of growing commercial focus • Strong clinical validation (BMS, Pfizer) for TYK2 and TYK2/JAK1 in psoriasis and psoriatic arthritis • Mid- and late- stage cli
Slide 9: We are Focused on Selective, Potent TYK2/JAK1 Inhibitors
We are Focused on Selective, Potent TYK2/JAK1 Inhibitors Significant clear opportunities available to Sareum • No marketed products with selectivity for TYK2 – recent target for therapeutic intervention • Few dual TYK2/JAK1 inhibitors in clinical trials – important for differentiation • No selective
Slide 10: Advancing our Pipeline
Advancing our Pipeline Lead Candidate Clinical Clinical Target Preclinical Potential indications optimisation selection Phase I Phase II Autoimmune Psoriasis, RA, lupus, IBD, MS diseases Severe SDC-1801 Proprietary TYK2/JAK1 Respiratory Acute respiratory symptoms of viral infections, including Covid
Slide 11: SDC-1801 – Autoimmune Diseases
SDC-1801 – Autoimmune Diseases Development Timeline • Internal focus on progressing SDC-1801 into first-in-human (Phase 1a/b) clinical trial • Initial focus on psoriasis • Clinical studies to be conducted at a specialist centre in Manchester, UK Q3 2022 Q4 2022 2023 2024 File CTA Initiate Phase 1a C
Slide 12: SDC-1802: Targeting Multiple Cancers
SDC-1802: Targeting Multiple Cancers • Good efficacy in immunotherapy disease models vs many cancers • Anti-tumour effects seen in models of kidney, colorectal & skin cancers and B-cell lymphoma • Evidence that SDC-1802 induces anti-cancer activity through a novel immunotherapeutic mechanism • Posit
Slide 13: SRA737: Current Development Status
SRA737: Current Development Status Sierra Oncology Corporate Presentation (Dated March 2022) • $550,000 milestone payment to Sareum upon achievement of the next milestone event (first patient in next clinical trial) • Eligible for up to $79.75M in total milestone payments, plus royalties • Future up
Slide 14: Potential Value Inflection Points
Potential Value Inflection Points • TYK2/JAK1 • SDC-1801 CTA submission (July 2022) ✓ • Selection of initial indication for Phase 1b trial ✓ • CTA approval by MHRA Proprietary • Phase 1a clinical trial start for SDC-1801 (Q4 2022)* pipeline • Updates on SDC-1802 preclinical progress Chk1 • (SRA737)
Slide 15: Thank you for joining us
Specialists in Small Molecule Drug Development Thank you for joining us Please submit any questions via “Ask a Question” Although the Company may not be able to answer every question it receives, it will seek to address the most prominent questions within the confines of information already disclose
Sareum Holdings — Investor Presentation (August 2022) on 6ix